PE20121066A1 - Derivados de diazahomoadamantano y metodos para usarlos - Google Patents

Derivados de diazahomoadamantano y metodos para usarlos

Info

Publication number
PE20121066A1
PE20121066A1 PE2011002111A PE2011002111A PE20121066A1 PE 20121066 A1 PE20121066 A1 PE 20121066A1 PE 2011002111 A PE2011002111 A PE 2011002111A PE 2011002111 A PE2011002111 A PE 2011002111A PE 20121066 A1 PE20121066 A1 PE 20121066A1
Authority
PE
Peru
Prior art keywords
diazatricilo
undecane
pyridin
ilcarbonyl
phenyl
Prior art date
Application number
PE2011002111A
Other languages
English (en)
Inventor
Michael R Schrimpf
Kevin B Sippy
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43354879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121066(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PE20121066A1 publication Critical patent/PE20121066A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE X ES CH2, C=O; R ES H, TIENO[2,3-c]PIRIDIN-5-ILCARBONIL, 5,5-DIOXIDODIBENZO[b,d]TIEN-3-IL, 2,5-DIMETIBENZOIL, [2-(TRIFLUOROMETIL)FENIL]ACETIL, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-(TIENO[2,3-c]PIRIDIN-5-ILCARBONIL)-1,4-DIAZATRICILO[4,3,1,13,8]UNDECANO; 4-(3-CLOROBENZOIL)-1,4-DIAZATRICILO[4,3,1,13,8]UNDECANO; N-[4-(1,4-DIAZATRICILO[4,3,1,13,8]UNDECAN-4-ILCARBONIL)FENIL]ACETAMIDA; 4-[5-(2,6-DIMETOXIFENIL)PIRIDIN-3-IL]-1,4-DIAZATRICILO[4,3,1,13,8]UNDECANO; 4-(6-CLORO-1,3-BENZOXAZOL-2-IL)-1,4-DIAZATRICICLO[4,3,1,13,8]UNDECANO; ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES SELECTIVOS DE NNR NEURONALES QUE COMPRENDEN ALFA7, ALFA4BETA2 UTILES EN EL TRATAMIENTO DE DEMENCIA SENIL, ENFERMEDAD DE PICK, DEMENCIA ASOCIADA AL SINDROME DE DOWN, DOLOR AGUDO, CEFALEAS, DOLOR NOCICEPTIVO, ENTRE OTROS
PE2011002111A 2009-06-19 2010-06-18 Derivados de diazahomoadamantano y metodos para usarlos PE20121066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21847909P 2009-06-19 2009-06-19

Publications (1)

Publication Number Publication Date
PE20121066A1 true PE20121066A1 (es) 2012-09-13

Family

ID=43354879

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002111A PE20121066A1 (es) 2009-06-19 2010-06-18 Derivados de diazahomoadamantano y metodos para usarlos

Country Status (15)

Country Link
US (1) US8846661B2 (es)
EP (1) EP2443122B1 (es)
JP (1) JP2012530084A (es)
KR (1) KR20120044978A (es)
CN (1) CN102459268A (es)
AU (1) AU2010262643B2 (es)
BR (1) BRPI1015043A2 (es)
CA (1) CA2765466A1 (es)
IL (2) IL216883A (es)
MX (1) MX2011014019A (es)
NZ (1) NZ597511A (es)
PE (1) PE20121066A1 (es)
RU (2) RU2549551C2 (es)
SG (1) SG176921A1 (es)
WO (1) WO2010145208A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2606052B1 (en) 2010-08-20 2016-06-01 Research Triangle Institute Nicotinic receptor compounds
CN103087001A (zh) * 2011-11-03 2013-05-08 南京大学 香草酸的1，3，4-噁二唑衍生物及其制法和用途
US10301294B2 (en) 2013-03-13 2019-05-28 The Broad Institute Inc. Compounds for the treatment of tuberculosis
RU2552649C1 (ru) * 2013-12-13 2015-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет тонких химических технологий имени М.В. Ломоносова" (МИТХТ им. М.В. Ломоносова) Душистые 5-бензил-1,3-диазаадамантан-6-оны
WO2015103005A1 (en) * 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CA2988968A1 (en) 2015-06-10 2016-12-15 Forum Pharmaceuticals, Inc. Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
KR20220100719A (ko) * 2015-12-10 2022-07-15 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
KR20200130287A (ko) * 2018-02-08 2020-11-18 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 헤테로아릴 화합물, 이의 약학 조성물 및 이의 치료적 용도
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
BR112020026534A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos de heteroarila para o tratamento da doença de huntington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557865A (en) * 1984-05-07 1985-12-10 Pennwalt Corporation Substituted 4-azatricyclo[4.3.1.13,8 ]undecane compounds
AU702720B2 (en) * 1995-11-02 1999-03-04 Neurosearch A/S Fused tropane-derivatives as neurotransmitter reuptake inhibitors
ID27544A (id) * 1998-08-18 2001-04-12 Ucb Sa Agonis dan antagonis muskarinat
CN1332726A (zh) * 1998-11-02 2002-01-23 卫福有限公司 吡咯烷化合物及其药物用途
WO2002100399A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
ATE363484T1 (de) * 2003-09-26 2007-06-15 Astrazeneca Ab Nichtamidnonane
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
WO2008118742A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof
MX2009010175A (es) * 2007-03-23 2009-10-12 Abbott Lab Derivados de acetamida y carboxamida de aza-adamantano y metodos de uso de los mismos.
EP2505588B1 (en) * 2007-03-23 2013-11-13 AbbVie Inc. process for preparing AMINOMETHYL AZAADAMANTANE DERIVATIVES as SELECTIVE MODULATORS OF THE ALPHA7- NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR (NNRS)
CN102639526B (zh) * 2009-09-14 2014-06-04 苏文生命科学有限公司 作为5-ht4受体配体的1,2-二氢-2-氧代喹啉化合物

Also Published As

Publication number Publication date
AU2010262643A1 (en) 2012-02-02
AU2010262643B2 (en) 2015-02-19
RU2015110025A (ru) 2015-08-20
IL216883A0 (en) 2012-02-29
US8846661B2 (en) 2014-09-30
CN102459268A (zh) 2012-05-16
KR20120044978A (ko) 2012-05-08
NZ597511A (en) 2014-01-31
EP2443122B1 (en) 2014-03-05
BRPI1015043A2 (pt) 2019-07-09
MX2011014019A (es) 2012-02-22
EP2443122A1 (en) 2012-04-25
SG176921A1 (en) 2012-01-30
CA2765466A1 (en) 2010-12-23
IL236830A0 (en) 2015-03-31
RU2012101784A (ru) 2013-07-27
RU2549551C2 (ru) 2015-04-27
IL216883A (en) 2015-02-26
JP2012530084A (ja) 2012-11-29
US20100324027A1 (en) 2010-12-23
WO2010145208A1 (en) 2010-12-23
EP2443122A4 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
AR053569A1 (es) Derivados de pirazol
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
IL195882A (en) Crystalline forms of derivatives of (1 s) –1, 5 – anhydro – 1– c - (3 - ((phenyl) methyl) phenyl) - d -glucitol with amino acids and their use in the treatment of diabetes
UY29246A1 (es) Nuevos compuestos
PE20141557A1 (es) Derivado de pirazoloquinolina
WO2009082268A3 (ru) ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
DE602006014789D1 (de) Verfahren zur Herstellung von Polyolefinen mit Vinyliden und Gruppen, die nichtaromatische heterocyclische Verbindungen verwenden
PE20120834A1 (es) Derivados de furopirimidindiona como moduladores de trpa1
BR112015007937A2 (pt) formas cristalinas de um inibidor de fator xia
DE602008003322D1 (de) Pyrrolo (3, 2, 1-ij) chinolin-4-on-derivate zur behandlung von tuberkulose
WO2009065922A3 (de) Organische verbindungen
NZ597511A (en) Diazahomoadamantane derivatives and methods of use thereof
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
EP1792899A4 (en) PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO DERIVATIVES
NO20075022L (no) (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav
AR082075A1 (es) Derivados de dioxima eter microbicidas
AR044336A1 (es) Tratamientos de ansiedad con ziprasidona
PE20080941A1 (es) Compuestos triciclicos como agonistas del receptor de melatonina
PE20080143A1 (es) Compuestos 2-oxo-3-fenil-(1,4-diazaespiro[4.5]dec-3-en-1-il)acetamida sustituidos como inhibidores del transportador de glicina
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
PE20100737A1 (es) Nuevos compuestos
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
AR037611A1 (es) Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas

Legal Events

Date Code Title Description
FD Application declared void or lapsed